{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:16:12Z","timestamp":1790421372168,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["14225"],"award-info":[{"award-number":["14225"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC id. 21113"],"award-info":[{"award-number":["AIRC id. 21113"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF2316780"],"award-info":[{"award-number":["RF2316780"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente\u201d project #2611752"],"award-info":[{"award-number":["Ricerca Corrente\u201d project #2611752"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["POR SATIN"],"award-info":[{"award-number":["POR SATIN"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The biological behavior of epithelial ovarian cancer (EOC) is unique since EOC cells metastasize early to the peritoneum. Thereby, new anti-target agents designed to block trans-coelomic dissemination of EOC cells may be useful as anti-metastatic drugs. The Urokinase Plasminogen Activator Receptor (uPAR) is overexpressed in EOC tissues, and its truncated forms released in sera and\/or ascitic fluid are associated with poor prognosis and unfavorable clinical outcome. We documented that uPAR triggers intra-abdominal dissemination of EOC cells through the interaction of its 84\u201395 sequence with the Formyl Peptide Receptor type 1 (FPR1), even as short linear peptide Ser-Arg-Ser-Arg-Tyr (SRSRY). While the pro-metastatic role of uPAR is well documented, little information regarding the expression and role of FPR1 in EOC is currently available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Expression levels of uPAR and FPR1 in EOC cells and tissues were assessed by immunofluorescence, Western blot, or immunohystochemistry. Cell adhesion to extra-cellular matrix proteins and mesothelium as well as mesothelium invasion kinetics by EOC cells were monitored using the xCELLigence technology or assessed by measuring cell-associated fluorescence. Cell internalization of FPR1 was identified on multiple z-series by confocal microscopy. Data from in vitro assays were analysed by one-way ANOVA and post-hoc Dunnett t-test for multiple comparisons. Tissue microarray data were analyzed with the Pearson\u2019s Chi-square (\u03c7<jats:sup>2<\/jats:sup>) test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Co-expression of uPAR and FPR1 by SKOV-3 and primary EOC cells confers a marked adhesion to vitronectin. The extent of cell adhesion decreases to basal level by pre-exposure to anti-uPAR84\u201395 Abs, or to the RI-3 peptide, blocking the uPAR84\u201395\/FPR1 interaction. Furthermore, EOC cells exposed to RI-3 or desensitized with an excess of SRSRY, fail to adhere also to mesothelial cell monolayers, losing the ability to cross them. Finally, primary and metastatic EOC tissues express a high level of FPR1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings identify for the first time FPR1 as a potential biomarker of aggressive EOC and suggests that inhibitors of the uPAR84\u201395\/FPR1 crosstalk may be useful for the treatment of metastatic EOC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13046-019-1465-8","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:55:52Z","timestamp":1573224952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion"],"prefix":"10.1186","volume":"38","author":[{"given":"Michele","family":"Minopoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Gigantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Ragone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Motti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosu\u00e8","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Greggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cono","family":"Scaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Patrizia","family":"Stoppelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia Simona","family":"Losito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vincenza","family":"Carriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9\u201332.","journal-title":"Cancer Biol Med"},{"issue":"11","key":"1465_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"Melina Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust T\u00c5, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol; 2019. https:\/\/doi.org\/10.1016\/S1470-2045(19)30456-5 . In press.","journal-title":"The Lancet Oncology"},{"key":"1465_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015: Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"1465_CR5","first-page":"517","volume":"123","author":"RGW Verhaak","year":"2013","unstructured":"Verhaak RGW, Tamayo P, Yang J-Y, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517\u201325.","journal-title":"J Clin Invest"},{"key":"1465_CR6","doi-asserted-by":"publisher","unstructured":"Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014;106(5). https:\/\/doi.org\/10.1093\/jnci\/dju048 . PMID:24700803","DOI":"10.1093\/jnci\/dju048"},{"key":"1465_CR7","doi-asserted-by":"publisher","unstructured":"Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106(10). https:\/\/doi.org\/10.1093\/jnci\/dju249 . PMID:25269487","DOI":"10.1093\/jnci\/dju249"},{"key":"1465_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(16)30108-5","volume":"17","author":"M Bagnoli","year":"2016","unstructured":"Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 2016;17:1137\u201346.","journal-title":"Lancet Oncol"},{"key":"1465_CR9","doi-asserted-by":"publisher","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","volume":"217","author":"M Petrillo","year":"2017","unstructured":"Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217:334.e1\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"1465_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet"},{"key":"1465_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143\u20138.","journal-title":"Gynecol Oncol"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","volume":"31","author":"KL Sodek","year":"2012","unstructured":"Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell\u2013cell and cell\u2013matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012;31:397\u2013414.","journal-title":"Cancer Metastasis Rev"},{"key":"1465_CR13","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/onc.2013.321","volume":"33","author":"E Lengyel","year":"2014","unstructured":"Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, et al. Epithelial ovarian cancer experimental models. Oncogene. 2014;33:3619\u201333.","journal-title":"Oncogene"},{"key":"1465_CR14","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.2174\/138161211796718143","volume":"17","author":"MV Carriero","year":"2011","unstructured":"Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011;17:1944\u201361.","journal-title":"Curr Pharm Des"},{"key":"1465_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1593\/neo.12442","volume":"14","author":"NN Al-Hassan","year":"2012","unstructured":"Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, et al. Differential roles of uPAR in peritoneal ovarian Carcinomatosis. Neoplasia. 2012;14:259\u201370.","journal-title":"Neoplasia"},{"issue":"3","key":"1465_CR16","first-page":"957","volume":"36","author":"P Leandersson","year":"2016","unstructured":"Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, H\u00f8yer-Hansen G, Borgfeldt C. A biomarker panel increases the diagnostic performance for epithelial ovarian cancer type I and II in young women. Anticancer Res. 2016;36(3):957\u201365.","journal-title":"Anticancer Res"},{"key":"1465_CR17","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1158\/1078-0432.CCR-08-0096","volume":"14","author":"E Heni\u0107","year":"2008","unstructured":"Heni\u0107 E, Borgfeldt C, Christensen IJ, Cassl\u00e9n B, H\u00f8yer-Hansen G. Cleaved forms of the Urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res. 2008;14:5785\u201393.","journal-title":"Clin Cancer Res"},{"key":"1465_CR18","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2174\/092986708785909012","volume":"15","author":"B Jacobsen","year":"2008","unstructured":"Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem. 2008;15:2559\u201373.","journal-title":"Curr Med Chem"},{"key":"1465_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1023\/A:1023099415940","volume":"22","author":"N Sidenius","year":"2003","unstructured":"Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205\u201322.","journal-title":"Cancer Metastasis Rev"},{"key":"1465_CR20","doi-asserted-by":"crossref","first-page":"18224","DOI":"10.1016\/S0021-9258(19)37176-5","volume":"267","author":"G H\u00f8yer-Hansen","year":"1992","unstructured":"H\u00f8yer-Hansen G, R\u00f8nne E, Solberg H, Behrendt N, Ploug M, Lund LR, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:18224\u20139.","journal-title":"J Biol Chem"},{"key":"1465_CR21","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2174\/138945011797635902","volume":"12","author":"IK Lund","year":"2011","unstructured":"Lund IK, Illemann M, Thurison T, Christensen IJ, H\u00f8yer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011;12:1744\u201360.","journal-title":"Curr Drug Targets"},{"key":"1465_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00018-007-6498-z","volume":"64","author":"C Yuan","year":"2007","unstructured":"Yuan C, Huang M. Does the urokinase receptor exist in a latent form? Cell Mol Life Sci. 2007;64:1033\u20137.","journal-title":"Cell Mol Life Sci"},{"key":"1465_CR23","doi-asserted-by":"publisher","first-page":"33544","DOI":"10.1074\/jbc.M111.220087","volume":"286","author":"H G\u00e5rdsvoll","year":"2011","unstructured":"G\u00e5rdsvoll H, Jacobsen B, Kriegbaum MC, Behrendt N, Engelholm L, \u00d8stergaard S, et al. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem. 2011;286:33544\u201356.","journal-title":"J Biol Chem"},{"key":"1465_CR24","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1093\/emboj\/16.24.7279","volume":"16","author":"F Fazioli","year":"1997","unstructured":"Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279\u201386.","journal-title":"EMBO J"},{"key":"1465_CR25","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1073\/pnas.022652999","volume":"99","author":"M Resnati","year":"2002","unstructured":"Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1\/LXA4R. Proc Natl Acad Sci U S A. 2002;99:1359\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1465_CR26","doi-asserted-by":"publisher","first-page":"25225","DOI":"10.1074\/jbc.M412605200","volume":"280","author":"L Gargiulo","year":"2005","unstructured":"Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem. 2005;280:25225\u201332.","journal-title":"J Biol Chem"},{"key":"1465_CR27","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.18632\/oncotarget.1930","volume":"5","author":"K Bifulco","year":"2014","unstructured":"Bifulco K, Votta G, Ingangi V, Carluccio GD, Rea D, Losito S, et al. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Oncotarget. 2014;5:4154\u201369.","journal-title":"Oncotarget"},{"key":"1465_CR28","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1111\/j.1538-7836.2010.04075.x","volume":"8","author":"K Bifulco","year":"2010","unstructured":"Bifulco K, Longanesi-Cattani I, Gala M, DI Carluccio G, Masucci MT, Pavone V, et al. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost. 2010;8:2789\u201399.","journal-title":"J Thromb Haemost"},{"key":"1465_CR29","doi-asserted-by":"publisher","first-page":"54474","DOI":"10.18632\/oncotarget.9976","volume":"7","author":"V Ingangi","year":"2016","unstructured":"Ingangi V, Bifulco K, Yousif AM, Ragone C, Motti ML, Rea D, et al. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Oncotarget. 2016;7:54474\u201387.","journal-title":"Oncotarget"},{"key":"1465_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/08923970600625975","volume":"28","author":"MA Panaro","year":"2006","unstructured":"Panaro MA, Acquafredda A, Sisto M, Lisi S, Maffione AB, Mitolo V. Biological role of the N-Formyl peptide receptors. Immunopharmacol Immunotoxicol. 2006;28:103\u201327.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1465_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/jnci\/dji142","volume":"97","author":"Y Zhou","year":"2005","unstructured":"Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst. 2005;97:823\u201335.","journal-title":"J Natl Cancer Inst"},{"key":"1465_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.febslet.2008.03.001","volume":"582","author":"K Bifulco","year":"2008","unstructured":"Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, et al. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett. 2008;582:1141\u20136.","journal-title":"FEBS Lett"},{"key":"1465_CR33","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1158\/1535-7163.MCT-09-0174","volume":"8","author":"MV Carriero","year":"2009","unstructured":"Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther. 2009;8:2708\u201317.","journal-title":"Mol Cancer Ther"},{"key":"1465_CR34","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1535-7163.MCT-13-0077","volume":"12","author":"K Bifulco","year":"2013","unstructured":"Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, Masucci MT, et al. A Urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting. Mol Cancer Ther. 2013;12:1981\u201393.","journal-title":"Mol Cancer Ther"},{"key":"1465_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-13-0949","volume":"13","author":"MV Carriero","year":"2014","unstructured":"Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, et al. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency. Mol Cancer Ther. 2014;13:1092\u2013104.","journal-title":"Mol Cancer Ther"},{"key":"1465_CR36","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41598-017-01425-9","volume":"7","author":"MV Carriero","year":"2017","unstructured":"Carriero MV, Bifulco K, Ingangi V, Costantini S, Botti G, Ragone C, et al. Retro-inverso Urokinase receptor antagonists for the treatment of metastatic sarcomas. Sci Rep. 2017;7:1312.","journal-title":"Sci Rep"},{"key":"1465_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-017-0650-x","volume":"36","author":"C Ragone","year":"2017","unstructured":"Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, et al. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. J Exp Clin Cancer Res. 2017;36:180.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1465_CR38","doi-asserted-by":"publisher","first-page":"12169","DOI":"10.1038\/s41598-019-47900-3","volume":"9","author":"M Minopoli","year":"2019","unstructured":"Minopoli M, Polo A, Ragone C, Ingangi V, Ciliberto G, Pessi A, Sarno S, Budillon A, Costantini S, Carriero MV. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity. Sci Rep. 2019;9(1):12169.","journal-title":"Sci Rep"},{"key":"1465_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/030089160809400411","volume":"94","author":"K Bifulco","year":"2008","unstructured":"Bifulco K, De Chiara A, Fazioli F, Longanesi-Cattani I, Cantelmo AR, Tirino V, et al. Cell invasiveness in sarcomas: a possibly useful clinical correlation. Tumori. 2008;94:505\u201310.","journal-title":"Tumori"},{"key":"1465_CR40","first-page":"1299","volume":"3","author":"MV Carriero","year":"1997","unstructured":"Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res. 1997;3:1299\u2013308.","journal-title":"Clin Cancer Res"},{"key":"1465_CR41","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs, vol. 6. 4th ed: 2014. 9789283244875. IARC. http:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Iarc-Classification-Of-Tumours"},{"key":"1465_CR42","doi-asserted-by":"publisher","first-page":"21727","DOI":"10.3390\/ijms141121727","volume":"14","author":"M Cantile","year":"2013","unstructured":"Cantile M, Scognamiglio G, La Sala L, La Mantia E, Scaramuzza V, Valentino E, et al. Aberrant expression of posterior HOX genes in well differentiated Histotypes of thyroid cancers. Int J Mol Sci. 2013;14:21727\u201340.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1465_CR43","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/ijms17071046","volume":"17","author":"Gerardo Botti","year":"2016","unstructured":"Botti G, Scognamiglio G, Cantile M. PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. Int J Mol Sci. 2016;17(7). https:\/\/doi.org\/10.3390\/ijms17071046 . PMID:27376268","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"1465_CR44","doi-asserted-by":"publisher","first-page":"e50195","DOI":"10.1371\/journal.pone.0050195","volume":"7","author":"C Gemperle","year":"2012","unstructured":"Gemperle C, Schmid M, Herova M, Marti-Jaun J, Wuest SJA, Loretz C, et al. Regulation of the Formyl peptide receptor 1 (FPR1) gene in primary human macrophages. PLoS One. 2012;7(11):e50195.","journal-title":"PLoS One"},{"key":"1465_CR45","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/sj.bjc.6602495","volume":"92","author":"N Ahmed","year":"2005","unstructured":"Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of \u03b16\u03b21 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer. 2005;92:1475\u201385.","journal-title":"Br J Cancer"},{"key":"1465_CR46","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1172\/JCI33775","volume":"118","author":"HA Kenny","year":"2008","unstructured":"Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118:1367\u201379.","journal-title":"J Clin Invest"},{"key":"1465_CR47","first-page":"231","volume":"29","author":"L Heyman","year":"2008","unstructured":"Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F. Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. TBI. 2008;29:231\u201344.","journal-title":"TBI"},{"key":"1465_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/CBI20090331","volume":"34","author":"L Heyman","year":"2010","unstructured":"Heyman L, Leroy-Dudal J, Fernandes J, Seyer D, Dutoit S, Carreiras F. Mesothelial vitronectin stimulates migration of ovarian cancer cells. Cell Biol Int. 2010;34:493\u2013502.","journal-title":"Cell Biol Int"},{"key":"1465_CR49","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-016-9791-0","volume":"33","author":"N Sluiter","year":"2016","unstructured":"Sluiter N, de Cuba E, Kwakman R, Kazemier G, Meijer G, te Velde EA. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metastasis. 2016;33:401\u201316.","journal-title":"Clin Exp Metastasis"},{"issue":"5","key":"1465_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14343\/JCSCR.2016.4e1005","volume":"4","author":"Gabriela Schneider","year":"2016","unstructured":"Gabriela Schneider, Malwina Suszynska, Sham Kakar, Mariusz Z Ratajczak. Vitronectin in the ascites of human ovarian carcinoma acts as a potent chemoattractant for ovarian carcinoma: Implication for metastasis by cancer stem cells. J Cancer Stem Cell Res. 2016;4:e1005. https:\/\/doi.org\/10.14343\/JCSCR.2016.4e1005 . PMCID: PMC5461934","journal-title":"Journal of Cancer Stem Cell Research"},{"key":"1465_CR51","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1158\/1078-0432.CCR-16-2811","volume":"23","author":"N Muhammad","year":"2017","unstructured":"Muhammad N, Bhattacharya S, Steele R, Phillips N, Ray RB. Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23:3120\u20138.","journal-title":"Clin Cancer Res"},{"key":"1465_CR52","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1084\/jem.181.4.1381","volume":"181","author":"J Bohuslav","year":"1995","unstructured":"Bohuslav J, Horejs\u00ed V, Hansmann C, St\u00f6ckl J, Weidle UH, Majdic O, et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995;181:1381\u201390.","journal-title":"J Exp Med"},{"key":"1465_CR53","first-page":"5307","volume":"59","author":"MV Carriero","year":"1999","unstructured":"Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, et al. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 1999;59:5307\u201314.","journal-title":"Cancer Res"},{"key":"1465_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1465_CR55","doi-asserted-by":"publisher","first-page":"e44806","DOI":"10.1371\/journal.pone.0044806","volume":"7","author":"K Bifulco","year":"2012","unstructured":"Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, et al. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS One. 2012;7:e44806.","journal-title":"PLoS One"},{"key":"1465_CR56","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.3390\/ijms12063409","volume":"12","author":"Y Wang","year":"2011","unstructured":"Wang Y, Liu J, Lin B, Wang C, Li Q, Liu S, et al. Study on the expression and clinical significances of Lewis y antigen and integrin \u03b1v, \u03b23 in epithelial ovarian tumors. Int J Mol Sci. 2011;12:3409\u201321.","journal-title":"Int J Mol Sci"},{"key":"1465_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fonc.2019.00082","volume":"9","author":"V Ingangi","year":"2019","unstructured":"Ingangi V, Minopoli M, Ragone C, Motti ML, Carriero MV. Role of microenvironment on the fate of disseminating cancer stem cells. Front Oncol. 2019;9:82.","journal-title":"Front Oncol"},{"key":"1465_CR58","doi-asserted-by":"publisher","unstructured":"Steven L. Gonias, Jingjing Hu. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015;6:154. https:\/\/doi.org\/10.3389\/fphar.2015.00154 . PMCID: PMC451554","DOI":"10.3389\/fphar.2015.00154"},{"key":"1465_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer- a proposed unifying theory. Am J Surg Pathol. 2010;34:433\u201343.","journal-title":"Am J Surg Pathol"},{"key":"1465_CR60","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS. 2011;108:7547\u201352.","journal-title":"PNAS"},{"key":"1465_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2016.00108","volume":"6","author":"SHL George","year":"2016","unstructured":"George SHL, Garcia R, Slomovitz BM. Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. Front Oncol. 2016;6:108.","journal-title":"Front Oncol"},{"key":"1465_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.7150\/thno.4953","volume":"3","author":"TV O\u2019Halloran","year":"2013","unstructured":"O\u2019Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery of Theranostic agents and Nanobins to multiple tumor compartments through a single target. Theranostics. 2013;3:496\u2013506.","journal-title":"Theranostics"},{"key":"1465_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2018.00024","volume":"8","author":"N Mahmood","year":"2018","unstructured":"Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24.","journal-title":"Front Oncol"},{"key":"1465_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.intimp.2015.08.036","volume":"37","author":"IA Schepetkin","year":"2016","unstructured":"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives. Int Immunopharmacol. 2016;37:43\u201358.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1465_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/molecules22030455","volume":"22","author":"Hui-Qiong He","year":"2017","unstructured":"Hui-Qiong He, Richard D. Ye. The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition. Molecules. 2017;22(3):455. https:\/\/doi.org\/10.3390\/molecules22030455 . PMCID: PMC6155412","journal-title":"Molecules"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1465-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T18:24:21Z","timestamp":1611858261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1465-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1465-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental protocols were performed in accordance with guidelines of the Istituto Nazionale Tumori \u201cFondazione G. Pascale\u201d-IRCCS (Quality System n. LRC 6019486\/QMS\/U\/IT- 2015 certificated in conformity with UNI EN ISO 9001:2008). The research work with primary cell lines and EOC tissues has been approved by Institutional Ethical Committee of Istituto Nazionale Tumori \u201cFondazione G. Pascale\u201d-IRCCS, Naples, Italy (protocol 258\/18, December 2018).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}